Lupin Limited, a global pharmaceutical leader, has announced the strategic acquisition of three prominent anti-diabetes trademarks—Gibtulio, Gibtulio Met, and Ajaduo—from Boehringer Ingelheim International GmbH. This acquisition is part of Lupin’s ongoing efforts to strengthen its diabetes portfolio in India, a key therapeutic segment for the company.

Key Details of the Acquisition

• Trademarks Acquired:
  • Gibtulio (empagliflozin)
  • Gibtulio Met (empagliflozin + metformin)
  • Ajaduo (empagliflozin + linagliptin)
• Terms of the Acquisition:
  • The trademark rights for these brands will be transferred to Lupin by March 2024.
  • Lupin has been marketing Gibtulio and Gibtulio Met since 2016, and Ajaduo since 2018, through co-marketing agreements with Boehringer Ingelheim India.

Anti-diabetic Product Information

The acquired products belong to a novel class of oral anti-diabetic drugs known as Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors and their combinations. These medications are primarily used to:

• Improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
• Empagliflozin, which is part of the acquired products, is additionally indicated to:
  • Reduce the risk of cardiovascular death in adults with type 2 diabetes.
  • Lower the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.

Growing Concern of Diabetes in India

India is facing a growing diabetes crisis, with the following key statistics:

• Over 80 million people over the age of 18 have diabetes.
• 25 million people are pre-diabetic.
• Awareness levels are alarmingly low, with more than 50% of the diabetic population unaware of their condition, leading to multiple health complications if not treated early.
• Additionally, adults with diabetes are at an increased risk of heart attack and stroke.

Strategic Significance on the Indian Healthcare Industry 

This acquisition is a key step for Lupin in solidifying its position as a leader in diabetes care in India. It comes at a time when the prevalence of diabetes and related lifestyle diseases is rapidly increasing, and the demand for effective, affordable treatment options is higher than ever. Through this acquisition, Lupin aims to deliver innovative and cost-effective solutions to millions of patients across India.

Statements from Key Officials

“Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India.” –Nilesh Gupta, Managing Director, Lupin

“The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India.” –Rajeev Sibal, President – India Region Formulations, Lupin

Also Read: AIIMS and Wipro GE Healthcare Sign MoU to Establish ‘AI Health Innovations Hub’ in New Delhi

Financial Impacts 

Lupin’s shares closed at ₹2,075.75 on December 13, marking a decline of ₹41.35, or 1.95%, on the Bombay Stock Exchange (BSE).

This acquisition marks a significant milestone for Lupin in its efforts to expand and enhance its diabetes portfolio. By acquiring the trademarks for Gibtulio, Gibtulio Met, and Ajaduo, Lupin is well-positioned to address the growing demand for diabetes care in India, where millions of patients are in need of effective and affordable treatment options. The move also reinforces Lupin’s commitment to providing high-quality healthcare solutions and improving patient outcomes in India.

Like 2

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!